Merck KGaA Acquires U.S. Proteomics Company ProteoPlex
Merck KGaA announced today that EMD Biosciences, Inc., its United States life sciences subsidiary located in San Diego, CA, has acquired ProteoPlex, Inc. of St. Louis, MO, privately owned research and development company specializing in functional genomics and proteomics. ProteoPlex will be a fully integrated part of EMD Biosciences. Both partners agreed not to disclose financial details of the transaction.
This acquisition provides Merck KGaA the opportunity to gain access to the emerging microarray market projected to approach USD 2 billion by the year 2008.
"The ProteoPlex brings a high level of sophisticated technology and personnel to Merck KGaA," said Dr. Bernd Reckman, Vice President and General Manager of Merck KGaA's Life Science Products Division. "Furthermore, the technology and competence of ProteoPlex are a perfect fit with our own proteomics R&D programs and will directly translate into new product offerings for our customers in the Life Sciences industry."
The ProteoPlex technology platform combines the power of parallel sample processing with the multiplex data generation capabilities of microarrays. "When you take the technology of ProteoPlex and the resources of Merck KGaA, you create a very powerful result," said David Smoller, Ph.D, President and CEO of ProteoPlex, Inc. "Moreover, the global sales and marketing leadership of Merck KGaA will provide accelerated access by customers to this important technology."
Other news from the department business & finance
